Extracellular vesicle-derived miR-141, miR-10b, miR-550a and miR-16 define a circulating signature in prostate cancer
A plasma microRNA signature distinguishes prostate cancer from benign conditions better than PSA alone in this preliminary study, requiring larger validation.
A plasma extracellular vesicle miRNA signature (miR-141, miR-10b, miR-550a, miR-16) distinguishes prostate cancer stages from BPH and healthy controls using qRT-PCR in this Turkish case-control study, offering a potential non-invasive complement to PSA-based screening with improved specificity for PCa vs BPH discrimination.
What the study was
- Study design
- Case-control observational study
- Population
- Healthy controls, BPH, localized PCa, metastatic PCa
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Irish Journal of Medical Science
Why it surfaced
EV-miRNA panel addresses PSA specificity gap — clinically relevant problem; needs prospective validation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.